FIELD: biotechnology.
SUBSTANCE: there are presented antibodies and their antigen-binding fragments specifically binding to CD73, and conjugates of said antibodies with a therapeutic agent or a label. Also disclosed are recovered nucleic acid molecules coding CD73 antibodies, as well as related expression vectors and host cells. A method of producing anti-CD73 antibodies is provided. Besides, the invention refers to pharmaceutical compositions containing the above antibodies, and to using the antibodies, conjugates and compositions for detecting CD73 protein in a sample and for treating cancer or fibrosis.
EFFECT: antibodies and their antigen-binding fragments bind to human CD73 with high affinity, inhibit CD73 enzymatic activity and induce CD73 internalisation.
21 cl, 44 dwg, 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SCLEROSTIN ANTIBODY, ITS ANTIGEN-BINDING FRAGMENT AND MEDICAL APPLICATION | 2016 |
|
RU2716101C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| ANTI-B7-H4 ANTIBODY AND DRUG CONJUGATE AND MEDICAL USE THEREOF | 2020 |
|
RU2827531C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
